Abstract:A single compound able to inhibit both Topo Ⅰ and Ⅱ may present the advantage of improving anti-proliferative activity,with reduced toxic side effects,with respect to the combination of two inhibitors.We designed and synthesized 28 compounds of indeno[1,2-b]indole derivatives as a new class of Topo Ⅰ and Ⅱ inhibitor and successfully identified compound 2-3j,which showed the most potent cell growth inhibition with IC50=0.74 μM against HCT-116 cell line.Compound 2-3j was also evaluated as a potent topoisomerase Ⅰ and Ⅱ inhibitor and can induce apoptosis in human colon cancer cells.2-3j showed potency against a small panel of drug sensitive and multidrug resistant (MDR) cell lines,and it reversed the MDR of K562/A02,MCF-7/Adr,and KB/Vcr cells at 0.5 μM,with reversal fold values of 3.2,10.1,and 5.8,respectively.2-3j might inhibit the function of ABCG2 to increase intracellular drug accumulation and enhance the sensitivity of conventional chemotherapeutic agents for MDR cells.2-3j could be a promising lead for the development of a new class of antitumor drug acting as inhibitors of Topo Ⅰ & Ⅱ and ABCG2.

The Discovery and Optimization of Novel Dual Inhibitors of Topoisomerase Ii and Histone Deacetylase

Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.

Design, synthesis and biological evaluation of dual Topo II/HDAC inhibitors bearing pyrimido[5,4-b]indole and pyrazolo[3,4-d]pyrimidine motifs.

Design, Synthesis and Anticancer Evaluation of Acridine Hydroxamic Acid Derivatives As Dual Topo and HDAC Inhibitors.

Discovery of Indolo[3,2- c]isoquinoline Derivatives as Novel Top1/2 Dual Inhibitors with Orally Efficacious Antitumor Activity and Low Toxicity

Indolo[3,2- c]isoquinoline Hydroxamic Acid Derivatives as Novel Orally Topoisomerase-Histone Deacetylase Dual Inhibitors for NSCLC Therapy

Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2.

Synthesis and biological evaluation of novel podophyllotoxin analogs as antitumor agents.

Pyrazolo [3,4-D]pyrimidine-based Dual HDAC/Topo II Inhibitors: Design, Synthesis, and Biological Evaluation As Potential Antitumor Agents

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies

Synthesis And Evaluation Of New Podophyllotoxin Derivatives With In Vitro Anticancer Activity

Synthesis and Evaluation of Novel Podophyllotoxin Derivatives As Potential Antitumor Agents.

Design, Synthesis and Anti-Tumor Activity of Novel Benzimidazole-Chalcone Hybrids as Non-Intercalative Topoisomerase II Catalytic Inhibitors

Novel 4β-anilino-podophyllotoxin derivatives: design synthesis and biological evaluation as potent DNA-topoisomerase II poisons and anti-MDR agents

Discovery of Chiral 1,4-Diarylazetidin-2-one-Based Hydroxamic Acid Derivatives as Novel Tubulin Polymerization Inhibitors with Histone Deacetylase Inhibitory Activity

Synthesis and Anticancer Research ofN-(2-aminophenyl)benzamide Acridine Derivatives as Dual Topoisomerase I and Isoform-Selective HDAC Inhibitors

Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy

Synthesis and biological evaluation of indeno[1, 2-b]indole derivatives as dual topoisomerase Ⅰ & Ⅱ inhibitors: novel multidrug resistant reversal anticancer agents

Novel 4 beta-anilino-podophyllotoxin derivatives: design synthesis and biological evaluation as potent DNA-topoisomerase II poisons and anti-MDR agents.

Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity